Investors

IR Overview

News

Date Title  
Toggle Summary Adaptimmune and Cryoport Announce Agreement to Ensure Safe and Fully Monitored Transport of Adaptimmune’s Cell Therapies
Key step toward commercial-readiness for ADP-A2M4 therapy with launch planned for 2022   PHILADELPHIA and OXFORDSHIRE, United Kingdom and IRVINE, Calif., Oct. 09, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, and Cryoport, Inc.
Adaptimmune and Cryoport Announce Agreement to Ensure Safe and Fully Monitored Transport of Adaptimmune’s Cell Therapies
Key step toward commercial-readiness for ADP-A2M4 therapy with launch planned for 2022   PHILADELPHIA and OXFORDSHIRE, United Kingdom and IRVINE, Calif., Oct. 09, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, and Cryoport, Inc.
Toggle Summary Adaptimmune Announces Appointment of Michael Garone as Interim Chief Financial Officer
PHILADELPHIA and OXFORDSHIRE, United Kingdom , Oct. 01, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, announces the appointment of Michael Garone as interim Chief Financial Officer (CFO) effective immediately.
Adaptimmune Announces Appointment of Michael Garone as Interim Chief Financial Officer
PHILADELPHIA and OXFORDSHIRE, United Kingdom , Oct. 01, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, announces the appointment of Michael Garone as interim Chief Financial Officer (CFO) effective immediately.
Toggle Summary Clear Benefit for Patients with Synovial Sarcoma Demonstrated in Updated Data from Ongoing Phase 1 Trial with ADP-A2M4 Presented at ESMO
- Clinical responses in 7 out of 12 patients with synovial sarcoma, and clinical benefit in 11 out 12 patients -   PHILADELPHIA and OXFORDSHIRE, United Kingdom , Sept. 30, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, presented
Clear Benefit for Patients with Synovial Sarcoma Demonstrated in Updated Data from Ongoing Phase 1 Trial with ADP-A2M4 Presented at ESMO
- Clinical responses in 7 out of 12 patients with synovial sarcoma, and clinical benefit in 11 out 12 patients -   PHILADELPHIA and OXFORDSHIRE, United Kingdom , Sept. 30, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, presented
Toggle Summary United States Orphan Drug Designation for Treatment of Soft Tissue Sarcomas Granted to SPEAR T-cells Targeting MAGE-A4
Orphan drug designation is another significant milestone in the ADP-A2M4 program PHILADELPHIA and OXFORDSHIRE, United Kingdom , Sept. 09, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that the United States Food and
United States Orphan Drug Designation for Treatment of Soft Tissue Sarcomas Granted to SPEAR T-cells Targeting MAGE-A4
Orphan drug designation is another significant milestone in the ADP-A2M4 program PHILADELPHIA and OXFORDSHIRE, United Kingdom , Sept. 09, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that the United States Food and
Toggle Summary Adaptimmune and Noile-Immune Announce Agreement to Develop SPEAR T-Cell Products expressing IL-7 and CCL19 as a next-generation treatment for cancer patients
The collaboration will develop Adaptimmune’s SPEAR T-cells in combination with Noile-Immune’s PRIME (IL-7 and CCL19) technology to improve proliferation and trafficking of T-cells to tackle solid tumors PHILADELPHIA and OXFORDSHIRE, United Kingdom, Aug.
Adaptimmune and Noile-Immune Announce Agreement to Develop SPEAR T-Cell Products expressing IL-7 and CCL19 as a next-generation treatment for cancer patients
The collaboration will develop Adaptimmune’s SPEAR T-cells in combination with Noile-Immune’s PRIME (IL-7 and CCL19) technology to improve proliferation and trafficking of T-cells to tackle solid tumors PHILADELPHIA and OXFORDSHIRE, United Kingdom, Aug.
Toggle Summary New Executive Team Announced at Adaptimmune
- Adrian Rawcliffe to assume CEO role from September 1, 2019 - - John Lunger promoted to Chief Patient Supply Officer from August 1, 2019 , as Adaptimmune gears up for commercial delivery of products to patients – - Rafael Amado , President R&D, will leave the Company on August 12, 2019 - - The
New Executive Team Announced at Adaptimmune
- Adrian Rawcliffe to assume CEO role from September 1, 2019 - - John Lunger promoted to Chief Patient Supply Officer from August 1, 2019 , as Adaptimmune gears up for commercial delivery of products to patients – - Rafael Amado , President R&D, will leave the Company on August 12, 2019 - - The
Toggle Summary Adaptimmune Reports Second Quarter 2019 Financial Results and Business Update
- Started SPEARHEAD-1 clinical trial with ADP-A2M4 in synovial sarcoma and MRCLS patients – - Started low-dose radiation sub-study with ADP-A2M4 with the MD Anderson Cancer Center - - Started SURPASS trial – the first next-generation clinical trial with ADP-A2M4CD8 – - Will complete ADP-A2M10
Adaptimmune Reports Second Quarter 2019 Financial Results and Business Update
- Started SPEARHEAD-1 clinical trial with ADP-A2M4 in synovial sarcoma and MRCLS patients – - Started low-dose radiation sub-study with ADP-A2M4 with the MD Anderson Cancer Center - - Started SURPASS trial – the first next-generation clinical trial with ADP-A2M4CD8 – - Will complete ADP-A2M10
Toggle Summary Adaptimmune to Report Second Quarter 2019 Financial Results and Business Update on Thursday, August 1, 2019
PHILADELPHIA and OXFORDSHIRE, United Kingdom , July 29, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will report financial results for the Second Quarter 2019 and provide a business update before the U.S.
Adaptimmune to Report Second Quarter 2019 Financial Results and Business Update on Thursday, August 1, 2019
PHILADELPHIA and OXFORDSHIRE, United Kingdom , July 29, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will report financial results for the Second Quarter 2019 and provide a business update before the U.S.
Toggle Summary Adaptimmune Starts SPEARHEAD-1 Trial with ADP-A2M4 SPEAR T-cells for patients with Synovial Sarcoma or MRCLS
- Compelling data reported with ADP-A2M4 SPEAR T-cells in synovial sarcoma - - Adaptimmune plans to launch a TCR T-cell therapy in 2022 - PHILADELPHIA and OXFORDSHIRE, United Kingdom , July 25, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat
Adaptimmune Starts SPEARHEAD-1 Trial with ADP-A2M4 SPEAR T-cells for patients with Synovial Sarcoma or MRCLS
- Compelling data reported with ADP-A2M4 SPEAR T-cells in synovial sarcoma - - Adaptimmune plans to launch a TCR T-cell therapy in 2022 - PHILADELPHIA and OXFORDSHIRE, United Kingdom , July 25, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat
Toggle Summary Adaptimmune Has Initiated a Radiation Sub-Study to Enhance Antitumor Activity Seen With ADP-A2M4 in Collaboration with The MD Anderson Cancer Center
- Compelling responses previously reported with ADP-A2M4 in sarcoma - - Use of low-dose radiation intended to enhance antitumor activity - PHILADELPHIA and OXFORDSHIRE, United Kingdom , July 22, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat
Adaptimmune Has Initiated a Radiation Sub-Study to Enhance Antitumor Activity Seen With ADP-A2M4 in Collaboration with The MD Anderson Cancer Center
- Compelling responses previously reported with ADP-A2M4 in sarcoma - - Use of low-dose radiation intended to enhance antitumor activity - PHILADELPHIA and OXFORDSHIRE, United Kingdom , July 22, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat
Toggle Summary Adaptimmune Starts the SURPASS Clinical Trial with its first Next-Generation SPEAR T-cells Targeting MAGE‑A4 to Enhance Antitumor Responses
These next-generation SPEAR T-cells may improve long term T-cell functions PHILADELPHIA and OXFORDSHIRE, United Kingdom , July 18, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc , Philadelphia, PA , and Oxfordshire, UK (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, has initiated
Adaptimmune Starts the SURPASS Clinical Trial with its first Next-Generation SPEAR T-cells Targeting MAGE‑A4 to Enhance Antitumor Responses
These next-generation SPEAR T-cells may improve long term T-cell functions PHILADELPHIA and OXFORDSHIRE, United Kingdom , July 18, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc , Philadelphia, PA , and Oxfordshire, UK (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, has initiated
Toggle Summary Adrian Rawcliffe to Succeed James Noble as Adaptimmune Chief Executive Officer
James Noble will transition to become a Non-Executive Director PHILADELPHIA and OXFORDSHIRE, United Kingdom , June 27, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP) today announced that Adrian Rawcliffe , currently Chief Financial Officer (CFO) of the Company, will succeed
Adrian Rawcliffe to Succeed James Noble as Adaptimmune Chief Executive Officer
James Noble will transition to become a Non-Executive Director PHILADELPHIA and OXFORDSHIRE, United Kingdom , June 27, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP) today announced that Adrian Rawcliffe , currently Chief Financial Officer (CFO) of the Company, will succeed
Toggle Summary Adaptimmune and Alpine Immune Sciences Announce Collaboration and License Agreement to Develop Next-Generation SPEAR T-Cell Products
- Adaptimmune to license Alpine’s Secreted and Transmembrane Immunomodulatory Protein technology for use with SPEAR T-cells to enhance antitumor responses - PHILADELPHIA and OXFORDSHIRE, United Kingdom, May 15, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell
Adaptimmune and Alpine Immune Sciences Announce Collaboration and License Agreement to Develop Next-Generation SPEAR T-Cell Products
- Adaptimmune to license Alpine’s Secreted and Transmembrane Immunomodulatory Protein technology for use with SPEAR T-cells to enhance antitumor responses - PHILADELPHIA and OXFORDSHIRE, United Kingdom, May 15, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell
Toggle Summary Adaptimmune Reports First Quarter 2019 Financial Results
- Clinical update issued in a separate announcement - - Financial guidance updated: funded into Q3 2020 - PHILADELPHIA and OXFORD, United Kingdom , May 06, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today reported financial
Adaptimmune Reports First Quarter 2019 Financial Results
- Clinical update issued in a separate announcement - - Financial guidance updated: funded into Q3 2020 - PHILADELPHIA and OXFORD, United Kingdom , May 06, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today reported financial
Toggle Summary Significant Clinical Progress as Adaptimmune Announces Responses with ADP-A2M4 in Synovial Sarcoma and Antitumor Activity in Other Solid Tumors
- Partial responses in 4 out of 5 synovial sarcoma patients treated with ~10 billion cells, with tumor shrinkage in nearly all assessed synovial sarcoma patients in the ADP-A2M4 pilot study -              - Initiating SPEARHEAD-1 trial in synovial sarcoma and myxoid/round cell liposarcoma with
Significant Clinical Progress as Adaptimmune Announces Responses with ADP-A2M4 in Synovial Sarcoma and Antitumor Activity in Other Solid Tumors
- Partial responses in 4 out of 5 synovial sarcoma patients treated with ~10 billion cells, with tumor shrinkage in nearly all assessed synovial sarcoma patients in the ADP-A2M4 pilot study -              - Initiating SPEARHEAD-1 trial in synovial sarcoma and myxoid/round cell liposarcoma with
Toggle Summary Adaptimmune to Present Data Demonstrating that its Off-the-shelf Process Produces T-cells from Stem Cells that Respond to Cancer Targets with a SPEAR TCR at ASGCT Meeting
- Data show strong progress with off-the-shelf program demonstrating T-cell differentiation from stem cells (hiPSC) in a serum-free process without the addition of mouse stromal cells - - Lentiviral transduction of hiPSC-derived cells with a SPEAR TCR produces transduced T-cells that can respond to
Adaptimmune to Present Data Demonstrating that its Off-the-shelf Process Produces T-cells from Stem Cells that Respond to Cancer Targets with a SPEAR TCR at ASGCT Meeting
- Data show strong progress with off-the-shelf program demonstrating T-cell differentiation from stem cells (hiPSC) in a serum-free process without the addition of mouse stromal cells - - Lentiviral transduction of hiPSC-derived cells with a SPEAR TCR produces transduced T-cells that can respond to
Toggle Summary Adaptimmune to Provide Clinical and Business Update on Monday May 6th, 2019
PHILADELPHIA and OXFORDSHIRE, United Kingdom , May 01, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will provide a clinical and business update before the U.S. markets open on Monday May 6, 2019.
Adaptimmune to Provide Clinical and Business Update on Monday May 6th, 2019
PHILADELPHIA and OXFORDSHIRE, United Kingdom , May 01, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will provide a clinical and business update before the U.S. markets open on Monday May 6, 2019.
Toggle Summary Adaptimmune Announces Oral Presentation of Allogeneic SPEAR T-cell Program at 2019 ASGCT Meeting
- Presentation to include overview of substantial progress of Adaptimmune’s off-the-shelf SPEAR T-cell platform - - Data will show that hiPSC-derived allogeneic SPEAR T-cells have a T-cell phenotype and demonstrate tumor antigen-specific activation in vitro - PHILADELPHIA and OXFORDSHIRE, United
Adaptimmune Announces Oral Presentation of Allogeneic SPEAR T-cell Program at 2019 ASGCT Meeting
- Presentation to include overview of substantial progress of Adaptimmune’s off-the-shelf SPEAR T-cell platform - - Data will show that hiPSC-derived allogeneic SPEAR T-cells have a T-cell phenotype and demonstrate tumor antigen-specific activation in vitro - PHILADELPHIA and OXFORDSHIRE, United
Toggle Summary Adaptimmune Presents Safety Data with Evidence of Tumor Necrosis in One Patient from ADP-A2AFP Study at American Association for Cancer Research (AACR) Meeting
PHILADELPHIA and OXFORD, United Kingdom , April 02, 2019 (GLOBE NEWSWIRE) --   Adaptimmune Therapeutics plc  (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, presented initial safety data from two patients with advanced hepatocellular carcinoma (HCC), liver cancer, from the first dose
Adaptimmune Presents Safety Data with Evidence of Tumor Necrosis in One Patient from ADP-A2AFP Study at American Association for Cancer Research (AACR) Meeting
PHILADELPHIA and OXFORD, United Kingdom , April 02, 2019 (GLOBE NEWSWIRE) --   Adaptimmune Therapeutics plc  (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, presented initial safety data from two patients with advanced hepatocellular carcinoma (HCC), liver cancer, from the first dose
Toggle Summary Adaptimmune Presents Preclinical Data for its Next Generation SPEAR T-cell Targeting MAGE-A4 at the American Association for Cancer Research (AACR) Annual Meeting
- Preclinical data show that next generation SPEAR T-cells may improve long term T-cell functions as well as antitumor activity - PHILADELPHIA and OXFORD, United Kingdom , April 01, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer,
Adaptimmune Presents Preclinical Data for its Next Generation SPEAR T-cell Targeting MAGE-A4 at the American Association for Cancer Research (AACR) Annual Meeting
- Preclinical data show that next generation SPEAR T-cells may improve long term T-cell functions as well as antitumor activity - PHILADELPHIA and OXFORD, United Kingdom , April 01, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer,
Toggle Summary CORRECTING and REPLACING -- Adaptimmune Reports Fourth Quarter / Full Year 2018 Financial Results and Business Update
PHILADELPHIA and OXFORD, United Kingdom , Feb. 27, 2019 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by  Adaptimmune Therapeutics plc  (Nasdaq:ADAP), please note that the third subheadline should read, "Treating patients in expansion phases of all ADP-A2M10 and
CORRECTING and REPLACING -- Adaptimmune Reports Fourth Quarter / Full Year 2018 Financial Results and Business Update
PHILADELPHIA and OXFORD, United Kingdom , Feb. 27, 2019 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by  Adaptimmune Therapeutics plc  (Nasdaq:ADAP), please note that the third subheadline should read, "Treating patients in expansion phases of all ADP-A2M10 and
Toggle Summary Adaptimmune Reports Fourth Quarter / Full Year 2018 Financial Results and Business Update
- On track for clinical data update from trials in multiple solid tumors at the Q1 2019 earnings update call in May - - Completed initial safety cohorts for ADP-A2M10 (MAGE-A10) in lung and triple tumor studies as well as ADP-A2M4 (MAGE-A4) basket study - - Treating patients in expansion phases of
Adaptimmune Reports Fourth Quarter / Full Year 2018 Financial Results and Business Update
- On track for clinical data update from trials in multiple solid tumors at the Q1 2019 earnings update call in May - - Completed initial safety cohorts for ADP-A2M10 (MAGE-A10) in lung and triple tumor studies as well as ADP-A2M4 (MAGE-A4) basket study - - Treating patients in expansion phases of
Toggle Summary Adaptimmune to Report Fourth Quarter / Full Year 2018 Financial Results and Business Update on Wednesday, February 27, 2019
PHILADELPHIA and OXFORD, United Kingdom , Feb. 07, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will announce financial results for the Fourth Quarter / Full Year 2018 and provide a general business update before the U.S.
Adaptimmune to Report Fourth Quarter / Full Year 2018 Financial Results and Business Update on Wednesday, February 27, 2019
PHILADELPHIA and OXFORD, United Kingdom , Feb. 07, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will announce financial results for the Fourth Quarter / Full Year 2018 and provide a general business update before the U.S.
Toggle Summary Dose Escalation in Liver Cancer Study with ADP-A2AFP (AFP) SPEAR T-cells and Moving to Expansion Phase in ADP-A2M10 (MAGE-A10) Lung Cancer Study after Favorable Safety Reviews
PHILADELPHIA and OXFORD, United Kingdom , Jan. 07, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that the Safety Review Committee (SRC) has endorsed dose escalation in the ongoing ADP-A2AFP (AFP) study in patients
Dose Escalation in Liver Cancer Study with ADP-A2AFP (AFP) SPEAR T-cells and Moving to Expansion Phase in ADP-A2M10 (MAGE-A10) Lung Cancer Study after Favorable Safety Reviews
PHILADELPHIA and OXFORD, United Kingdom , Jan. 07, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that the Safety Review Committee (SRC) has endorsed dose escalation in the ongoing ADP-A2AFP (AFP) study in patients
Toggle Summary Adaptimmune Announces that Gwen Binder will leave in January 2019
PHILADELPHIA and OXFORD, United Kingdom , Dec. 12, 2018 (GLOBE NEWSWIRE) -- Adaptimmune (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, today announced that Gwen Binder , PhD, Chief Technology Officer, will be leaving the company at the end of January 2019 . Dr.
Adaptimmune Announces that Gwen Binder will leave in January 2019
PHILADELPHIA and OXFORD, United Kingdom , Dec. 12, 2018 (GLOBE NEWSWIRE) -- Adaptimmune (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, today announced that Gwen Binder , PhD, Chief Technology Officer, will be leaving the company at the end of January 2019 . Dr.
Toggle Summary Adaptimmune Reports Third Quarter 2018 Financial Results and Business Update
Progressed to expansion phase for MAGE-A10 triple tumor and MAGE-A4 basket studies after favorable safety review of Cohort 3 data with target doses of 5 billion cells Continued dosing in Cohort 1 of AFP study, with anticipated dose escalation to Cohort 2 early 2019  ~$26 million upon completion of
Adaptimmune Reports Third Quarter 2018 Financial Results and Business Update
Progressed to expansion phase for MAGE-A10 triple tumor and MAGE-A4 basket studies after favorable safety review of Cohort 3 data with target doses of 5 billion cells Continued dosing in Cohort 1 of AFP study, with anticipated dose escalation to Cohort 2 early 2019  ~$26 million upon completion of
Toggle Summary Adaptimmune to Report Third Quarter 2018 Financial Results and Business Update on Tuesday, November 6, 2018
PHILADELPHIA and OXFORD, United Kingdom , Oct. 25, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will announce financial results for the Third Quarter 2018 and provide a general business update before the U.S.
Adaptimmune to Report Third Quarter 2018 Financial Results and Business Update on Tuesday, November 6, 2018
PHILADELPHIA and OXFORD, United Kingdom , Oct. 25, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will announce financial results for the Third Quarter 2018 and provide a general business update before the U.S.
Toggle Summary Updated Data from Ongoing MAGE-A10 and MAGE-A4 Studies Presented at the 2018 ESMO Congress
PHILADELPHIA and OXFORD, United Kingdom , Oct. 20, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, presented initial data from the first two cohorts of its ongoing studies with its MAGE-A10 and MAGE-A4 SPEAR T-cells
Updated Data from Ongoing MAGE-A10 and MAGE-A4 Studies Presented at the 2018 ESMO Congress
PHILADELPHIA and OXFORD, United Kingdom , Oct. 20, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, presented initial data from the first two cohorts of its ongoing studies with its MAGE-A10 and MAGE-A4 SPEAR T-cells
Toggle Summary Data Updates from Ongoing MAGE-A10 Studies and MAGE-A4 Study to be presented at the European Society for Medical Oncology (ESMO) 2018 Congress
PHILADELPHIA and OXFORD, United Kingdom , Oct. 08, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, today announced further details about two poster presentations at the upcoming ESMO congress, as follows: MAGE-A10
Data Updates from Ongoing MAGE-A10 Studies and MAGE-A4 Study to be presented at the European Society for Medical Oncology (ESMO) 2018 Congress
PHILADELPHIA and OXFORD, United Kingdom , Oct. 08, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, today announced further details about two poster presentations at the upcoming ESMO congress, as follows: MAGE-A10
Toggle Summary Adaptimmune Therapeutics plc Announces Closing of Registered Direct Offering of American Depositary Shares
PHILADELPHIA, Pa. and OXFORD, U.K. , Sept. 07, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, today announced the closing of its previously announced registered direct offering of its American Depositary Shares
Adaptimmune Therapeutics plc Announces Closing of Registered Direct Offering of American Depositary Shares
PHILADELPHIA, Pa. and OXFORD, U.K. , Sept. 07, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, today announced the closing of its previously announced registered direct offering of its American Depositary Shares
Toggle Summary Adaptimmune Therapeutics plc Announces Registered Direct Offering of American Depositary Shares
PHILADELPHIA and OXFORD, United Kingdom , Sept. 05, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, today announced that it has entered into a definitive agreement with Matrix Capital Management Company, LP
Adaptimmune Therapeutics plc Announces Registered Direct Offering of American Depositary Shares
PHILADELPHIA and OXFORD, United Kingdom , Sept. 05, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, today announced that it has entered into a definitive agreement with Matrix Capital Management Company, LP
Toggle Summary Third Dosing Cohort to be initiated in MAGE-A4 SPEAR T-cell Basket Study After Favorable Review of Safety from One Billion Cell Dose Cohort
PHILADELPHIA and OXFORD, United Kingdom , Aug. 15, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced a favorable review of safety data from the second dose cohort of patients who received one billion transduced
Third Dosing Cohort to be initiated in MAGE-A4 SPEAR T-cell Basket Study After Favorable Review of Safety from One Billion Cell Dose Cohort
PHILADELPHIA and OXFORD, United Kingdom , Aug. 15, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced a favorable review of safety data from the second dose cohort of patients who received one billion transduced
Toggle Summary Adaptimmune Reports Second Quarter 2018 Financial Results and Business Update
- Dosing patients in both MAGE-A10 pilot studies in third cohort with range of one to six billion cells - - NY-ESO program transitioned to GSK allows clinical focus on wholly owned assets - - Guidance confirmed, funded through to early 2020 - - Conference call to be held today at 8:00 a.m.
Adaptimmune Reports Second Quarter 2018 Financial Results and Business Update
- Dosing patients in both MAGE-A10 pilot studies in third cohort with range of one to six billion cells - - NY-ESO program transitioned to GSK allows clinical focus on wholly owned assets - - Guidance confirmed, funded through to early 2020 - - Conference call to be held today at 8:00 a.m.
Toggle Summary Adaptimmune to Report Second Quarter 2018 Financial Results and Business Update on Thursday August 2, 2018
PHILADELPHIA and OXFORD, United Kingdom , July 26, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will announce financial results for the Second Quarter 2018 and provide a general business update before the U.S.
Adaptimmune to Report Second Quarter 2018 Financial Results and Business Update on Thursday August 2, 2018
PHILADELPHIA and OXFORD, United Kingdom , July 26, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will announce financial results for the Second Quarter 2018 and provide a general business update before the U.S.
Toggle Summary GSK and Adaptimmune Complete Transition of NY-ESO SPEAR T-cell Therapy Program to GSK
LONDON and OXFORD, United Kingdom , July 24, 2018 (GLOBE NEWSWIRE) -- GlaxoSmithKline plc and Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced the transition of the development program for GSK3377794 (GSK ‘794), an NY-ESO SPEAR T-cell therapy,
GSK and Adaptimmune Complete Transition of NY-ESO SPEAR T-cell Therapy Program to GSK
LONDON and OXFORD, United Kingdom , July 24, 2018 (GLOBE NEWSWIRE) -- GlaxoSmithKline plc and Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced the transition of the development program for GSK3377794 (GSK ‘794), an NY-ESO SPEAR T-cell therapy,
Toggle Summary Adaptimmune Announces Favorable Review of Safety from One Billion Cell Dose Cohort in MAGE-A10 SPEAR T-cell Study and Initiation of Third Dosing Cohorts
PHILADELPHIA and OXFORD, United Kingdom , July 18, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced favorable review of safety data from the second dose cohort of patients who received one billion transduced
Adaptimmune Announces Favorable Review of Safety from One Billion Cell Dose Cohort in MAGE-A10 SPEAR T-cell Study and Initiation of Third Dosing Cohorts
PHILADELPHIA and OXFORD, United Kingdom , July 18, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced favorable review of safety data from the second dose cohort of patients who received one billion transduced
Toggle Summary Study published in Cancer Discovery Indicates that NY-ESO SPEAR T-cells are Long-lived, Self‑renewing, and Capable of Persistent Anti-Tumor Effects
Data indicate that self-renewing pools of SPEAR T-cells can produce a continuous supply of effector cells capable of mediating sustained antitumor effects PHILADELPHIA and OXFORD, United Kingdom , June 11, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell
Study published in Cancer Discovery Indicates that NY-ESO SPEAR T-cells are Long-lived, Self‑renewing, and Capable of Persistent Anti-Tumor Effects
Data indicate that self-renewing pools of SPEAR T-cells can produce a continuous supply of effector cells capable of mediating sustained antitumor effects PHILADELPHIA and OXFORD, United Kingdom , June 11, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell
Toggle Summary Adaptimmune Announces First Patient to Receive One Billion Target Cell Dose after Positive Safety Data from Pilot Study with MAGE-A4 SPEAR T-cells
- No evidence of off-target toxicity at 100 million cells for second wholly owned asset -                - Synovial sarcoma and MRCLS added to the seven solid tumors already in the MAGE-A4 basket study - PHILADELPHIA, Pa. and OXFORD, U.K. , June 04, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics
Adaptimmune Announces First Patient to Receive One Billion Target Cell Dose after Positive Safety Data from Pilot Study with MAGE-A4 SPEAR T-cells
- No evidence of off-target toxicity at 100 million cells for second wholly owned asset -                - Synovial sarcoma and MRCLS added to the seven solid tumors already in the MAGE-A4 basket study - PHILADELPHIA, Pa. and OXFORD, U.K. , June 04, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics
Toggle Summary Adaptimmune Presents Detailed Safety Update from Ongoing MAGE-A10 Pilot Studies at ASCO
- Acceptable safety profile with no evidence of off-target toxicity in 100 million cell safety cohorts -  - Dosing continues with the one billion “target” cell dose - PHILADELPHIA, Pa. and OXFORD, U.K. , June 04, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in
Adaptimmune Presents Detailed Safety Update from Ongoing MAGE-A10 Pilot Studies at ASCO
- Acceptable safety profile with no evidence of off-target toxicity in 100 million cell safety cohorts -  - Dosing continues with the one billion “target” cell dose - PHILADELPHIA, Pa. and OXFORD, U.K. , June 04, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in
Toggle Summary Updated Myxoid/Round Cell Liposarcoma Data with NY-ESO, Presented at ASCO Annual Meeting, Further Supports Promising Benefit: Risk Profile
PHILADELPHIA and OXFORD, United Kingdom , June 02, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, presented initial data from the ongoing pilot study of NY-ESO SPEAR T-cells in myxoid/round cell liposarcoma (MRCLS).
Updated Myxoid/Round Cell Liposarcoma Data with NY-ESO, Presented at ASCO Annual Meeting, Further Supports Promising Benefit: Risk Profile
PHILADELPHIA and OXFORD, United Kingdom , June 02, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, presented initial data from the ongoing pilot study of NY-ESO SPEAR T-cells in myxoid/round cell liposarcoma (MRCLS).
Toggle Summary Myxoid/Round Cell Liposarcoma Data with NY-ESO and MAGE-A10 Study Update to be Presented at American Association for Clinical Oncology (ASCO) Annual Meeting
PHILADELPHIA and OXFORD, U.K. , May 16, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will release updated data from ongoing clinical studies at the annual ASCO meeting at McCormick Place in Chicago, Illinois .
Myxoid/Round Cell Liposarcoma Data with NY-ESO and MAGE-A10 Study Update to be Presented at American Association for Clinical Oncology (ASCO) Annual Meeting
PHILADELPHIA and OXFORD, U.K. , May 16, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will release updated data from ongoing clinical studies at the annual ASCO meeting at McCormick Place in Chicago, Illinois .
Toggle Summary Adaptimmune Reports First Quarter 2018 Financial Results and Business Update
- Dosing patients in MAGE-A10 lung cancer study at one billion target cell dose - - Updated MRCLS response data will be presented in an oral presentation at ASCO -  - Guidance confirmed, funded through to early 2020 - - Conference call to be held today at 8:00 a.m. EDT ( 1:00 p.m.
Adaptimmune Reports First Quarter 2018 Financial Results and Business Update
- Dosing patients in MAGE-A10 lung cancer study at one billion target cell dose - - Updated MRCLS response data will be presented in an oral presentation at ASCO -  - Guidance confirmed, funded through to early 2020 - - Conference call to be held today at 8:00 a.m. EDT ( 1:00 p.m.
Toggle Summary Adaptimmune to Report First Quarter 2018 Financial Results and Business Update on Wednesday May 9, 2018
PHILADELPHIA and OXFORD, U.K. , April 25, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will announce financial results for the First Quarter 2018 and provide a general business update before the open of the U.S.
Adaptimmune to Report First Quarter 2018 Financial Results and Business Update on Wednesday May 9, 2018
PHILADELPHIA and OXFORD, U.K. , April 25, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will announce financial results for the First Quarter 2018 and provide a general business update before the open of the U.S.
Toggle Summary Adaptimmune Presents MAGE-A4 and MAGE-A10 pre-clinical data at American Association for Cancer Research (AACR) Annual Meeting
- Preclinical testing raises no safety concerns for MAGE A4 - - Refined preclinical testing strategy expected to further mitigate risk of unexpected off-target toxicity - PHILADELPHIA, Pa. and OXFORD, United Kingdom , April 16, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a
Adaptimmune Presents MAGE-A4 and MAGE-A10 pre-clinical data at American Association for Cancer Research (AACR) Annual Meeting
- Preclinical testing raises no safety concerns for MAGE A4 - - Refined preclinical testing strategy expected to further mitigate risk of unexpected off-target toxicity - PHILADELPHIA, Pa. and OXFORD, United Kingdom , April 16, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a
Toggle Summary Adaptimmune Announces Changes to Board of Directors
PHILADELPHIA, Pa. and OXFORD, U.K. , April 12, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that, in a planned transition, John Furey has been appointed as an independent Non-Executive Director, and Peter Thompson ,
Adaptimmune Announces Changes to Board of Directors
PHILADELPHIA, Pa. and OXFORD, U.K. , April 12, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that, in a planned transition, John Furey has been appointed as an independent Non-Executive Director, and Peter Thompson ,
Toggle Summary Adaptimmune to Present Two Posters at the Upcoming American Association for Cancer Research (AACR) Annual Meeting
PHILADELPHIA, Pa. and OXFORD, U.K. , April 06, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will present two posters summarizing preclinical research with its MAGE-A4 and MAGE-A10 SPEAR T-cells at the upcoming AACR meeting at
Adaptimmune to Present Two Posters at the Upcoming American Association for Cancer Research (AACR) Annual Meeting
PHILADELPHIA, Pa. and OXFORD, U.K. , April 06, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will present two posters summarizing preclinical research with its MAGE-A4 and MAGE-A10 SPEAR T-cells at the upcoming AACR meeting at
Toggle Summary Adaptimmune Announces Responses in Second Solid Tumor Indication with NY-ESO SPEAR T-cells
Data provides confirmation of broad applicability of SPEAR TCR T-cell platform in solid tumors PHILADELPHIA and OXFORD, U.K. , March 15, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today reported three partial responses (two
Adaptimmune Announces Responses in Second Solid Tumor Indication with NY-ESO SPEAR T-cells
Data provides confirmation of broad applicability of SPEAR TCR T-cell platform in solid tumors PHILADELPHIA and OXFORD, U.K. , March 15, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today reported three partial responses (two
Toggle Summary Adaptimmune Reports Fourth Quarter / Full Year 2017 Financial Results and Business Update
- Responses observed in second solid tumor with NY-ESO providing further evidence of the potential of our SPEAR TCR T‑cell therapies to treat solid tumors - - Clinical momentum continues: dosing patients in MAGE-A4 “basket” study at 100 million cell dose level - - Guidance confirmed: funded through
Adaptimmune Reports Fourth Quarter / Full Year 2017 Financial Results and Business Update
- Responses observed in second solid tumor with NY-ESO providing further evidence of the potential of our SPEAR TCR T‑cell therapies to treat solid tumors - - Clinical momentum continues: dosing patients in MAGE-A4 “basket” study at 100 million cell dose level - - Guidance confirmed: funded through
Toggle Summary Adaptimmune to Report Fourth Quarter / Full Year 2017 Financial Results and Business Update on Thursday March 15, 2018
PHILADELPHIA and OXFORD, United Kingdom , March 05, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will announce financial results for the Fourth Quarter / Full Year 2017 and provide a general business update before the open of the
Adaptimmune to Report Fourth Quarter / Full Year 2017 Financial Results and Business Update on Thursday March 15, 2018
PHILADELPHIA and OXFORD, United Kingdom , March 05, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will announce financial results for the Fourth Quarter / Full Year 2017 and provide a general business update before the open of the
Toggle Summary Adaptimmune Announces Positive Safety Data from Pilot Studies with MAGE-A10 SPEAR T-cells and First Patient to Receive 1 billion Target Cell Dose
PHILADELPHIA and OXFORD, United Kingdom , Jan. 08, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced initial safety data from its two ongoing pilot studies of SPEAR T-cells targeting MAGE-A10, one in non-small cell lung
Adaptimmune Announces Positive Safety Data from Pilot Studies with MAGE-A10 SPEAR T-cells and First Patient to Receive 1 billion Target Cell Dose
PHILADELPHIA and OXFORD, United Kingdom , Jan. 08, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced initial safety data from its two ongoing pilot studies of SPEAR T-cells targeting MAGE-A10, one in non-small cell lung